You are here » Home » Companies » Company Overview » Lupin Ltd

Lupin Ltd.

BSE: 500257	Sector: Health care
NSE: LUPIN	ISIN Code: INE326A01037

BSE 00:00 | 20 May

638.40

3.70
(0.58%)

OPEN

634.70

HIGH

645.40

LOW

626.35

NSE 00:00 | 20 May

638.40

3.55
(0.56%)

OPEN

636.00

HIGH

646.00

LOW

626.00

Add to Watchlist | Add to Portfolio

OPEN	634.70
PREVIOUS CLOSE	634.70
VOLUME	73288
52-Week high	1267.50
52-Week low	620.35
P/E
Mkt Cap.(Rs cr)	29,015
Buy Price	0.00
Buy Qty	0.00
Sell Price	0.00
Sell Qty	0.00

OPEN	634.70
CLOSE	634.70
VOLUME	73288
52-Week high	1267.50
52-Week low	620.35
P/E
Mkt Cap.(Rs cr)	29,015
Buy Price	0.00
Buy Qty	0.00
Sell Price	0.00
Sell Qty	0.00

Lupin Ltd. (LUPIN) - News Sector

Amazon, Flipkart in talks to buy stake in $1 bn diagnostic chain Metropolis

12.45 am | 21 May 2022 | Bloomberg

Metropolis runs more than 3,000 diagnostics centers as well as pathology laboratories in India and Africa
Board evaluating Sebi penalty of Rs 1 crore, says Fortis Healthcare

11.33 pm | 20 May 2022 | Business Standard

Market regulator SEBI slapped a fine on Fortis Healthcare subsidiaries on account of fund diversion by erstwhile promoters
Zydus Lifesciences Q4 net dips to 24% Rs 397 cr, revenue up 5%

11.31 pm | 20 May 2022 | Business Standard

Company says operational performance came amid geopolitical turmoil resulting in supply chain challenges and inflationary pressures
Dr Reddy's sees sharpest intra-day rally since Sept 2020; stock surges 8%

2.33 pm | 20 May 2022 | Business Standard

The stock gained 9 per cent in two days after the pharma company reported better-than-expected revenue growth in March quarter (Q4FY22).
Dr Reddy's Labs Q4 PAT falls 76% on pricing pressure, low export benefit

1.08 am | 20 May 2022 | Business Standard

Dr Reddy's Q4 results: The revenue was up 15% to Rs 5,437 crore for the quarter under review
Dr Reddy's plans new brands in Russia, says no issue with funds in country

12.55 am | 20 May 2022 | Business Standard

The company's Russian revenue was at Rs 686 crore for Q4FY22, a year-on-year growth of 70%.
Lupin slips 9%, hits 2-year low on disappointing March quarter results

9.39 am | 19 May 2022 | Business Standard

Lupin's performance was skewed on revenues front amid US and India posting lower than expected sales while RoW and South Africa saw better than antici...
How Prathap Chandra Reddy propelled Apollo Hospitals into a new orbit

9.35 pm | 18 May 2022 | Business Standard

The struggle that he went through in setting up a private health care facility in the India of the 1980s is part of folklore
We aim to test 500,000 patients a day in 5 years: Dr Lal PathLabs CMD

9.25 pm | 18 May 2022 | Business Standard

Dr Lal PathLabs is India's largest diagnostic services player by revenue, with 289 laboratories across the country
Caring for patients runs in our DNA, say Cipla's Samina Hamied, Umang Vohra

9.22 pm | 18 May 2022 | Business Standard

'Cipla has so many capabilities that for anything we need to do, we say we can do it'
Rejuvenating Cipla: After global expansion, acquisitions on cards

9.18 pm | 18 May 2022 | Business Standard

Having consolidated its presence across geographies, the pharma major is looking at acquisitions
Dr Reddy's Q4 PAT may rise 28% YoY; margins likely to fall, say analysts

3.16 pm | 18 May 2022 | Business Standard

The pharmaceutical giant may witness some impact due to its large exposure of the business to Russia, and CIS regions.
Dr Lal Pathlabs slips 6%, hits 52-week low post muted Q4 results

9.52 am | 18 May 2022 | Business Standard

In Q4FY22, normalised earnings before interest, taxes, depreciation, and amortization (EBITDA) margins contracted 630 bps to 19.4 per cent from 25.7 p...
Dr Lal Pathlabs Q4 consolidated PAT dips 27% to Rs 62 cr, stock sheds 1%

1.47 am | 18 May 2022 | Business Standard

Operating revenue rose 12.7% during the quarter to Rs 485.5 cr; Covid-19 and allied segments added roughly 13.6% to Q4 top line
Aurobindo hits 2-year low; dips 11% in a week on USFDA's 6 observations

12.42 pm | 17 May 2022 | Business Standard

Analysts at ICICI Securities expect Aurobindo Pharma's adjusted PAT to de-grow 30.4 per cent year-on-year (YoY) to Rs 557.90 crore in the March 2022 q...
GlaxoSmithKline Pharma reports consolidated net loss of Rs 55 crore

1.05 am | 17 May 2022 | Press Trust of India

Revenue from operations rose to Rs 810 crore for the fourth quarter, compared with Rs 744 crore in the year-ago period, the pharmaceutical major said ...
USFDA rush after 2-year lull: 20-30% new products may be open to inspection

3.01 am | 16 May 2022 | Business Standard

The last two years saw limited physical inspections due to travel restrictions during the pandemic
A first in India: Zydus brings new drug for uncontrolled 'bad' cholesterol

12.04 am | 14 May 2022 | Business Standard

Uncontrolled LDL-c, which poses a major risk of cardiovascular diseases, lacked proper treatment despite patients' lifestyle changes and use of statin...
Cipla looks to invest more in mRNA tech; holds discussions with firms

2.03 am | 12 May 2022 | Business Standard

Speaking to Business Standard, Samina Hamied, executive vice chairperson, Cipla, says one must invest in research and development (R&D) to feed the co...
Cipla will use Covid-19 bulk drugs inventory when demand rises

11.46 pm | 11 May 2022 | Business Standard

The Covid-19 portfolio contributed 5-6 per cent of Cipla's turnover during peak Covid waves, the firm said